Cargando…

Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials

BACKGROUND: Numerous statistical methods can be used to calculate the confidence interval (CI) of risk differences. There is consensus in previous literature that the Wald method should be discouraged. We compared five statistical methods for estimating the CI of risk difference in terms of CI width...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Anthony D., Komorowski, Adam S., Lo, Carson K. L., Tandon, Pranav, Li, Xena X., Mokashi, Vaibhav, Cvetkovic, Anna, Findlater, Aidan, Liang, Laurel, Tomlinson, George, Loeb, Mark, Mertz, Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520289/
https://www.ncbi.nlm.nih.gov/pubmed/34656155
http://dx.doi.org/10.1186/s13063-021-05686-8
_version_ 1784584639853101056
author Bai, Anthony D.
Komorowski, Adam S.
Lo, Carson K. L.
Tandon, Pranav
Li, Xena X.
Mokashi, Vaibhav
Cvetkovic, Anna
Findlater, Aidan
Liang, Laurel
Tomlinson, George
Loeb, Mark
Mertz, Dominik
author_facet Bai, Anthony D.
Komorowski, Adam S.
Lo, Carson K. L.
Tandon, Pranav
Li, Xena X.
Mokashi, Vaibhav
Cvetkovic, Anna
Findlater, Aidan
Liang, Laurel
Tomlinson, George
Loeb, Mark
Mertz, Dominik
author_sort Bai, Anthony D.
collection PubMed
description BACKGROUND: Numerous statistical methods can be used to calculate the confidence interval (CI) of risk differences. There is consensus in previous literature that the Wald method should be discouraged. We compared five statistical methods for estimating the CI of risk difference in terms of CI width and study conclusion in antibiotic non-inferiority trials. METHODS: In a secondary analysis of a systematic review, we included non-inferiority trials that compared different antibiotic regimens, reported risk differences for the primary outcome, and described the number of successes and/or failures as well as patients in each arm. For each study, we re-calculated the risk difference CI using the Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and skewness-corrected asymptotic score (SCAS) methods. The CIs by different statistical methods were compared in terms of CI width and conclusion on non-inferiority. A wider CI was considered to be more conservative. RESULTS: The analysis included 224 comparisons from 213 studies. The statistical method used to calculate CI was not reported in 134 (59.8%) cases. The median (interquartile range IQR) for CI width by Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and SCAS methods was 13.0% (10.8%, 17.4%), 13.3% (10.9%, 18.5%), 13.6% (11.1%, 18.9%), 13.6% (11.1% and 19.0%), and 13.4% (11.1%, 18.9%), respectively. In 216 comparisons that reported a non-inferiority margin, the conclusion on non-inferiority was the same across the five statistical methods in 211 (97.7%) cases. The differences in CI width were more in trials with a sample size of 100 or less in each group and treatment success rate above 90%. Of the 18 trials in this subgroup with a specified non-inferiority margin, non-inferiority was shown in 17 (94.4%), 16 (88.9%), 14 (77.8%), 14 (77.8%), and 15 (83.3%) cases based on CI by Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and SCAS methods, respectively. CONCLUSIONS: The statistical method used to calculate CI was not reported in the majority of antibiotic non-inferiority trials. Different statistical methods for CI resulted in different conclusions on non-inferiority in 2.3% cases. The differences in CI widths were highest in trials with a sample size of 100 or less in each group and a treatment success rate above 90%. TRIAL REGISTRATION: PROSPERO CRD42020165040. April 28, 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05686-8.
format Online
Article
Text
id pubmed-8520289
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85202892021-10-20 Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials Bai, Anthony D. Komorowski, Adam S. Lo, Carson K. L. Tandon, Pranav Li, Xena X. Mokashi, Vaibhav Cvetkovic, Anna Findlater, Aidan Liang, Laurel Tomlinson, George Loeb, Mark Mertz, Dominik Trials Research BACKGROUND: Numerous statistical methods can be used to calculate the confidence interval (CI) of risk differences. There is consensus in previous literature that the Wald method should be discouraged. We compared five statistical methods for estimating the CI of risk difference in terms of CI width and study conclusion in antibiotic non-inferiority trials. METHODS: In a secondary analysis of a systematic review, we included non-inferiority trials that compared different antibiotic regimens, reported risk differences for the primary outcome, and described the number of successes and/or failures as well as patients in each arm. For each study, we re-calculated the risk difference CI using the Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and skewness-corrected asymptotic score (SCAS) methods. The CIs by different statistical methods were compared in terms of CI width and conclusion on non-inferiority. A wider CI was considered to be more conservative. RESULTS: The analysis included 224 comparisons from 213 studies. The statistical method used to calculate CI was not reported in 134 (59.8%) cases. The median (interquartile range IQR) for CI width by Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and SCAS methods was 13.0% (10.8%, 17.4%), 13.3% (10.9%, 18.5%), 13.6% (11.1%, 18.9%), 13.6% (11.1% and 19.0%), and 13.4% (11.1%, 18.9%), respectively. In 216 comparisons that reported a non-inferiority margin, the conclusion on non-inferiority was the same across the five statistical methods in 211 (97.7%) cases. The differences in CI width were more in trials with a sample size of 100 or less in each group and treatment success rate above 90%. Of the 18 trials in this subgroup with a specified non-inferiority margin, non-inferiority was shown in 17 (94.4%), 16 (88.9%), 14 (77.8%), 14 (77.8%), and 15 (83.3%) cases based on CI by Wald, Agresti-Caffo, Newcombe, Miettinen-Nurminen, and SCAS methods, respectively. CONCLUSIONS: The statistical method used to calculate CI was not reported in the majority of antibiotic non-inferiority trials. Different statistical methods for CI resulted in different conclusions on non-inferiority in 2.3% cases. The differences in CI widths were highest in trials with a sample size of 100 or less in each group and a treatment success rate above 90%. TRIAL REGISTRATION: PROSPERO CRD42020165040. April 28, 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05686-8. BioMed Central 2021-10-16 /pmc/articles/PMC8520289/ /pubmed/34656155 http://dx.doi.org/10.1186/s13063-021-05686-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bai, Anthony D.
Komorowski, Adam S.
Lo, Carson K. L.
Tandon, Pranav
Li, Xena X.
Mokashi, Vaibhav
Cvetkovic, Anna
Findlater, Aidan
Liang, Laurel
Tomlinson, George
Loeb, Mark
Mertz, Dominik
Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials
title Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials
title_full Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials
title_fullStr Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials
title_full_unstemmed Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials
title_short Confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials
title_sort confidence interval of risk difference by different statistical methods and its impact on the study conclusion in antibiotic non-inferiority trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520289/
https://www.ncbi.nlm.nih.gov/pubmed/34656155
http://dx.doi.org/10.1186/s13063-021-05686-8
work_keys_str_mv AT baianthonyd confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT komorowskiadams confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT locarsonkl confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT tandonpranav confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT lixenax confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT mokashivaibhav confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT cvetkovicanna confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT findlateraidan confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT lianglaurel confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT tomlinsongeorge confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT loebmark confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT mertzdominik confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials
AT confidenceintervalofriskdifferencebydifferentstatisticalmethodsanditsimpactonthestudyconclusioninantibioticnoninferioritytrials